IDEXX Laboratories, Inc. (IDXX)

From the record

IDEXX Laboratories, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

IDEXX Laboratories, Inc.'s 10 filed years say what it did: revenue went from $1.8 billion in fiscal 2016 to $4.3 billion in fiscal 2025, up 10.3% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, IDEXX Laboratories, Inc.'s diluted share count shrank about 1.4% a year, and dividends and buybacks returned about 70% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 53 sales and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, IDEXX Laboratories, Inc. earned about 66 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 79 cents per dollar of everything the company owns. Leverage: it owed about 52 cents per dollar of assets, and net share issuance: its share count shrank 2.7% over the year (the filed statements).

From the record

IDEXX Laboratories, Inc.'s standing among 17 graded names in its industry family: revenue of $4.3 billion in fiscal 2025 ranks in the top 3% by size; a net margin of 24.6% ranks in the top 9%; revenue growth of 8.5% a year over the last 3 filed years ranks in the top 41% (its annual reports).

From the record

IDEXX Laboratories, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 20 officers and directors filing in the last fifteen months have been on the record a median of 7.5 years (top 11%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (top 43%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

IDEXX Laboratories, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $180 million against debt of $450 million leaves -8.1% of its assets as net cash, bottom 31% of its family; cash from operations less capital spending is 24.6% of revenue (top 9%); a gross margin of 61.8% (top 29%); research spending of 5.8% of revenue (bottom 22%) (its annual report).

From the record

IDEXX Laboratories, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 8.5% a year over the last three filed years against 10.3% over all 10, slowing (top 50% of its family); the newest year grew 10.4% (top 21%); research spending grew -0.5% a year (top 50%); capital spending grew -5.7% a year (top 30%) (its annual reports). IDEXX Laboratories, Inc. reported 2 product lines in fiscal 2025: Product at $2.5 billion (59%), Service at $1.8 billion (41%); 2 of 2 grew against the year before (its annual report).

From the record

IDEXX Laboratories, Inc.'s newest year against its own record: revenue of $4.3 billion in fiscal 2025 came in 2.6% above the $4.2 billion its prior three years' pace pointed to (top 43% of its family); net income of $1.1 billion against a prior three-year average of $804 million (top 28%); a net margin of 24.6% against 22% before (bottom 41%) (its annual reports).